DSM DSM
Company Profile ↓Company Overview
DSM (DSM) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 8.7.
Carries low leverage with a debt-to-equity ratio of 0.36.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Nov 2025 Revenue of $-4.57M (-113.6% YoY); net profit $-5.52M.
- Trailing 12 Months Year-on-year growth — revenue -113.6%, earnings -117.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -113.64% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -117.02% |
Stock Price Performance
| 1 Year: | +4.68% |
| 6 Months: | -3.59% |
| 3 Months: | -4.82% |
| 1 Month: | -2.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross2d ago
- RSI (14)33.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | Nov 2025 |
|---|---|---|---|---|---|
| Revenue | - | -70.38M | 10.06M | 33.49M | -4.57M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 1.07M | 967.00K | 1.09M | 947.69K |
| Operating Income | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| Interest Expense | - | 1.98M | 5.08M | 6.55M | 5.88M |
| Pretax Income | - | -71.45M | 9.09M | 32.40M | -5.52M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -71.45M | 9.09M | 32.40M | -5.52M |
| Diluted EPS | 0.50 | -1.46 | 0.19 | 0.66 | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | Nov 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 38.83M | 15.70M | -1.87M | 20.13M |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | - | -38.54M | -15.32M | 1.15M | -19.45M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | 38.83M | 15.70M | -1.87M | 20.13M |
| Net Change in Cash | - | 285.71K | 389.06K | -722.87K | 681.41K |
Ratios (Annual)
Figures in %.
| Metric | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | Nov 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | 101.5% | 90.4% | 96.8% | 120.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DSM
Enterprise value to EBIT forward of DSM-Firmenich AG – DUS:ZX6 - TradingView
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPTDdlVEhjQTNNZHJCVUU3cXA5RVZ3QUtCMkd1Qm9zeW1VR2dWN01TTktvcHlaeWNpeURsSGZmbWNDalQwMzdQLU5FVnRTZkhpTHR2Q2RFamdiMmNwekdKMkRlSGFTRjNjc1lQekZORDdGRmZEY1JQSk9DWGhQblVHazhSSkQtbFBISTd2OD…
DSM-Firmenich stock holds steady as investors eye 2025 results and nutrition portfolio - ad-hoc-news.de
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVjRMZVpLZGpZcjN2RlFTek9WY29rb253X3ZSRHRQbDhvaXI2UFIxOVZNUWx2OFNPdEp2TkZFSnNaSG51OGR6UmxwOXJCRWRhUExubW5sUzROS1JjUzFTaEduTDdQcy1Ccm8zV3V2UnFiSE5IVGZZeTBEaGpmajZpeFZqU3YydnE0OG04WU…
BNY Mellon Strategic Municipal Bond Fund, Inc. $DSM Shares Bought by Rivernorth Capital Management LLC - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOUHp0b01mNGJrWlV5YjFBUkRHM1YycS1tdHhYQnNwUXlKVTVJNC1mX0lRVkFqUlFxUloyX1VnUDdnWXlPei1aWDd1dnJBR2JOcHVlZnllUmpfcGtEWkRNNlpMbkx6T3dmSXNXSVZvdWVid2tUWS1Ma1BZakFSbW9CTzJzYVZzN1hnd2JTZk…
Price-Driven Insight from (DSM) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQcG1IODBpZ3FIS2FoR0FRR0ZzcWNYZ2FjTzU0b3lBRlRTb2s3UzZrdy05NW84bFZuRG1pRTdOLW11WkhVS0FVa2Q4S25fbDdXWFJfVXBLd3hBOFlibUVYMk1ReUtlRXVFck1HV1VzY3NDcFZYdVhudzRHbnZBVk82RlFLRGNTTklsczNnUk…
DSM-Firmenich Advances €500 Million Capital-Reducing Share Buyback - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxOY05OdnZ0TzZod3lmVlI5RDNuaUtfU2R1cWRGTWcxbVBrcEpEcUlHRlpGYm1xV0JrSHZHanc1SktHdDBpOEJHbGh6dTJ0OHJJYVpIT3Z2YlZtUzdoQ180LVdRQlUzTjhtY2RDNjU1WjlMS0pRMUJMN2xFR3NqbkNCRlpMa0JXaEFPdmU3Uz…
Dividend Investors: Don't Be Too Quick To Buy DSM-Firmenich AG (AMS:DSFIR) For Its Upcoming Dividend - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQUGlWUEk0TVdwQnF1YmprRDVZNy1WbnVtT1VWd0FkR1hIXzMzamVxbTA3TTlwX3UxVU5GaWVuM1JkSGxqbC1BWVNJSmpJZGxucEZBbXNYOW9MT2dkdnZiQ3E1VFBoTlZfSGVHZnNNVy12X1o0aklDY0JKbW9JRXJhbjNuUkt1Um9nQUh2N3…
DSM — Frequently Asked Questions
What is the current share price of DSM?
As of 2026-09-07 16:24 PDT, DSM trades at $5.72 on NASDAQ/NYSE. Its 52-week range is $5.46 to $6.12.
What is the P/E ratio of DSM?
DSM trades at a trailing price-to-earnings (P/E) ratio of 8.67.
Is DSM a good stock to buy?
This page provides a data-driven analysis of DSM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.